Adam covers proteomics and the clinical lab market for GenomeWeb.
CEO Jim Davis projected that factors including reimbursement changes, consumer-initiated testing, and acquisitions would yield growth in the company's base business.
The system, which will launch first in the EU and then the US and China, will be integrated into the company's existing Cobas Pro Integrated Solutions analyzer.
Launched in Europe in 2018 and the US in 2020, the fully automated mass spec-based analyzer failed to gain market traction, in large part due to a limited assay menu.
An overwhelming volume of arbitration requests has made it difficult for providers, including labs, to quickly challenge and resolve payment disputes under the law.
While reform of lab-developed test regulations and PAMA appeared possible at the beginning of 2022, in the end, the status quo won out.
The timelines the administration set this fall for ramping testing in the event of a health emergency are potentially doable but largely aspirational at the moment.
Lawmakers are still wrangling over whether to include these two key lab industry bills in an end-of-year spending package due to pass next week.
The AACC representative said that, as written, the exemption would not apply to large portions of laboratory-developed testing done at academic medical centers.
The firm opened a molecular testing lab near UPS's Louisville, Kentucky, hub that it said will let it deliver next-morning results to customers nationwide.
The survey also found that while implementation lagged awareness, roughly 30 percent of labs had switched to the new equations months after their introduction.